Abstract
To evaluate the effects of renin-angiotensin system (RAS)-targeting antihypertensive drugs and its classes on the incidence of vascular cognitive impairment (VCI). Pubmed, Embase, and Cochrane Library database of selected articles, and previous systematic reviews through May 2015 were searched. Studies that evaluated the association between use of RAS-targeting drugs and VCI were included. Relative risks (RRs) with 95% confidence intervals (CIs) were pooled using fixed effects models or random effects models. In all studies as a whole, the use of RAS-targeting drugs was significantly associated with a reduced risk of VCI (RR, 0.87; 95% CI, 0.75-0.98) and vascular dementia (VD) (RR, 0.78; 95% CI, 0.64-0.93), compared no use of RAS-targeting drugs. Subgroup analysis showed that subjects with Angiotensin-Converting Enzyme Inhibitors (ACEI) use significantly associated with a reduced incidence of VCI (RR, 0.81; 95% CI 0.70-0.91) and VD (RR, 0.75; 95% CI, 0.57-0.93); however, subjects with Angiotensin Receptor Blockers (ARB) use had not this effect on VCI (RR, 0.94; 95% CI 0.76-1.13) or VD (RR, 0.94; 95% CI, 0.45-1.44). In an analysis of subgroups, case-control studies found that the use of RAS-targeting drugs could effectively decr...Continue Reading
References
Jan 1, 1991·Alzheimer Disease and Associated Disorders·V C Hachinski
Nov 1, 1987·Acta Psychiatrica Scandinavica·A F JormA S Henderson
Sep 1, 1986·Controlled Clinical Trials·R DerSimonian, N Laird
Mar 12, 1997·JAMA : the Journal of the American Medical Association·D A SnowdonW R Markesbery
Oct 9, 2001·Lancet·UNKNOWN PROGRESS Collaborative Group
Mar 23, 2002·BMJ : British Medical Journal·Jackie BoschUNKNOWN HOPE Investigators. Heart outcomes prevention evaluation
Jul 12, 2002·Statistics in Medicine·Julian P T Higgins, Simon G Thompson
May 14, 2003·Archives of Internal Medicine·Christophe TzourioUNKNOWN PROGRESS Collaborative Group
Mar 3, 2005·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·Ihab HajjarPaul Eleazer
Oct 12, 2005·Hypertension·Sean P DidionFrank M Faraci
Aug 19, 2006·Stroke; a Journal of Cerebral Circulation·Vladimir HachinskiGabrielle G Leblanc
Feb 7, 2007·Hypertension·Jan A StaessenWillem H Birkenhäger
May 8, 2007·The American Journal of Geriatric Cardiology·Donna S Hanes, Matthew R Weir
Dec 28, 2007·Progress in Neurobiology·John W WrightJoseph W Harding
Sep 2, 2008·Lancet Neurology·Hans-Christoph DienerUNKNOWN Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) study group
Sep 23, 2009·Expert Review of Neurotherapeutics·Albert FournierNaoyuki Sato
Apr 8, 2010·Rejuvenation Research·Lusine DanielyanWilliam H Frey
Apr 10, 2010·Stroke; a Journal of Cerebral Circulation·Sarah T PendleburyPeter M Rothwell
Jul 16, 2010·Brain Research·Koji YamadaTomoyuki Kanda
Nov 26, 2010·Lancet Neurology·Ingmar Blümcke, Roberto Spreafico
Feb 8, 2011·PloS One·Donglin ZhuQiang Tong
Oct 11, 2011·Brain Research·Koji YamadaTomoyuki Kanda
Oct 20, 2011·BMJ : British Medical Journal·Julian P T HigginsUNKNOWN Cochrane Statistical Methods Group
Citations
Jul 9, 2016·International Journal of Cardiology·Yi-Chun KuanChia-Hung Kao
Feb 5, 2019·British Journal of Pharmacology·Romain BarusRégis Bordet
Nov 11, 2017·Journal of Neuro-oncology·Mudit ChowdharyKirtesh R Patel
May 5, 2020·Hypertension·Jessika RoyeaEdith Hamel
May 26, 2017·BMC Medicine·Régis BordetAlla Guekht
Sep 29, 2018·Journal of Internal Medicine·B PetekS Garcia-Ptacek
Jan 19, 2021·Curēus·Nupur MishraStacey E Heindl